![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
ACTIVITY OF ECD4-IG AGAINST CCR5 ANTAGONIST-RESISTANT HIV-1
|
|
|
Reported by Jules Levin
CROI 2019 March 4-7 Seattle
![0313191](../images/031319/031319-5/0313191.gif)
![0313192](../images/031319/031319-5/0313192.gif)
![0313193](../images/031319/031319-5/0313193.gif)
![0313194](../images/031319/031319-5/0313194.gif)
![0313195](../images/031319/031319-5/0313195.gif)
![0313196](../images/031319/031319-5/0313196.gif)
![0313197](../images/031319/031319-5/0313197.gif)
![0313198](../images/031319/031319-5/0313198.gif)
![0313199](../images/031319/031319-5/0313199.gif)
![03131910](../images/031319/031319-5/03131910.gif)
![03131911](../images/031319/031319-5/03131911.gif)
This work was supported in part by the grant from the National Institutes of Health/National Institute of Allergy and InfectiousDiseases (R37AI055357 ). Thanks the ACTG A5211 protocol team for providing the HIVDiseases (R37AI055357 ). Thanks the ACTG A5211 protocol team for providing the HIV-1 Env-genes of MCV-susceptible and -resistant viruses from a phase 2 trial of VCV.
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|